Home > Abstracts & Research > Abstracts > 2006 ASCO Annual Meeting
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Sub-category: Other: lung cancer Category: Lung Cancer Meeting: 2006 ASCO Annual Meeting Printer Friendly E-Mail Article
Abstract No: 17122 Citation: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17122 Author(s): R. Murthy, Y. Oh, A. Tam, S. Gupta, D. C. Madoff, B. Glisson Abstract: Background: Hepatic metastases are a common manifestation of primary lung malignancies; the primary and other extrahepatic sites are often less responsive to systemic therapy. A new method of regional therapy for hepatic metastases, called SIR-Spheres, a 32µ resin sphere incorporating a pure Beta emitter, Yttrium - 90, has advantages to older forms of regional hepatic therapy, used to treat colorectal liver metastases. The effectiveness and relatively response durability suggests a favorable alternative to chemotherapy for patients with liver-dominant metastatic lung cancers. We report our experience using SIR-Spheres in this setting. Materials and Methods: 6 patients (2 well differentiated carcinoid, 2 well & 1 poorly differentiated adenocarcinoma, 1 poorly differentiated small cell carcinoma) with unresectable hepatic metastases were treated with 8 infusions of SIR-Spheres after failing systemic chemotherapy, radiofrequency ablation or arterial embolization were included in the study. SIR-Spheres were administered as 2nd-6th line therapy. Median interval from diagnosis to SIR-Spheres treatment was 20.5 months (6-51 m). Results: Abdominal visceral arteriography demonstrated vasculature conducive for SIR-Spheres delivery in all patients. The median dose of 36.1 mCi (12.9-54 mCi) was delivered. SPECT - CT fusion Bremsstrahlung scans post therapy confirmed preferential deposition of SIR-Spheres within metastases. Responses to therapy included a decrease in the size of the hepatic metastases in one patient and stable disease in two patients. One patient had a mixed response and two patients had progression of disease. One Gr. III and one Gr. IV hepatic toxicity occurred. All patients experienced transient Gr. 1 or 2 fatigue. Time to progression of liver disease ranged from 3 to 9 months. Conclusion: SIR-Spheres is a feasible alternative to systemic therapy for patients with liver dominant metastases from lung cancers. Although serious hepatotoxicity was noted in patients with advanced liver metastases, the treatment was tolerated with only reversible fatigue in the majority of patients. When the treatment was effective, the duration of local disease control after one treatment equaled or exceeded what would be expected with chemotherapy.
Other Abstracts in this Sub-Category 1. Low dose spiral computed tomography for early diagnosis of lung cancer. Results of baseline screening in 5,000 high-risk volunteers. Meeting: 2006 ASCO Annual Meeting Abstract No: 7029 First Author: G. Veronesi Category: Lung Cancer - Other: lung cancer 2. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 7062 First Author: L. Fehrenbacher Category: Lung Cancer - Other: lung cancer 3. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Meeting: 2006 ASCO Annual Meeting Abstract No: 7079 First Author: P. J. Loehrer Sr. Category: Lung Cancer - Other: lung cancer More... Abstracts by R. Murthy 1. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 17122 First Author: R. Murthy Category: Lung Cancer - Other: lung cancer More... PubMed Articles by Ravi Murthy
1. Resin (90)Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys, United States Vol 65, No 2 (5/13/2006): pp. 412-25 PMID: 16690429 [PubMed - in process] 2. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer, Vol , No (9/1/2005): pp. PMID: 16134179 [PubMed - in process] 3. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics, United States Vol 25 Suppl 1, No (10/18/2005): pp. S41-55 PMID: 16227496 [PubMed - in process] More...
This online resource is supported by:
Terms & Conditions | Privacy Policy | Sponsor | Contact Us | Conflict of Interest
SEARCH
SIGN IN | REGISTER | ADVANCED SEARCH
1900 Duke Street, Suite 200 | Alexandria, VA 22314
Meetings Abstracts & Research Abstracts Virtual Meeting Annual Meeting Summaries NICCQ Central Review of Clinical Trials Grants Clinical Trials Awards Practice Resources Education & Training News Legislative & Regulatory
About ASCO ASCO Bookstore Careers in Oncology Downloads & Technology Grants Membership State Affiliates
Home > Abstracts & Research > Abstracts > 2006 ASCO Annual Meeting
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Sub-category: Other: lung cancer Category: Lung Cancer Meeting: 2006 ASCO Annual Meeting Printer Friendly E-Mail Article
Abstract No: 17122 Citation: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17122 Author(s): R. Murthy, Y. Oh, A. Tam, S. Gupta, D. C. Madoff, B. Glisson Abstract: Background: Hepatic metastases are a common manifestation of primary lung malignancies; the primary and other extrahepatic sites are often less responsive to systemic therapy. A new method of regional therapy for hepatic metastases, called SIR-Spheres, a 32µ resin sphere incorporating a pure Beta emitter, Yttrium - 90, has advantages to older forms of regional hepatic therapy, used to treat colorectal liver metastases. The effectiveness and relatively response durability suggests a favorable alternative to chemotherapy for patients with liver-dominant metastatic lung cancers. We report our experience using SIR-Spheres in this setting. Materials and Methods: 6 patients (2 well differentiated carcinoid, 2 well & 1 poorly differentiated adenocarcinoma, 1 poorly differentiated small cell carcinoma) with unresectable hepatic metastases were treated with 8 infusions of SIR-Spheres after failing systemic chemotherapy, radiofrequency ablation or arterial embolization were included in the study. SIR-Spheres were administered as 2nd-6th line therapy. Median interval from diagnosis to SIR-Spheres treatment was 20.5 months (6-51 m). Results: Abdominal visceral arteriography demonstrated vasculature conducive for SIR-Spheres delivery in all patients. The median dose of 36.1 mCi (12.9-54 mCi) was delivered. SPECT - CT fusion Bremsstrahlung scans post therapy confirmed preferential deposition of SIR-Spheres within metastases. Responses to therapy included a decrease in the size of the hepatic metastases in one patient and stable disease in two patients. One patient had a mixed response and two patients had progression of disease. One Gr. III and one Gr. IV hepatic toxicity occurred. All patients experienced transient Gr. 1 or 2 fatigue. Time to progression of liver disease ranged from 3 to 9 months. Conclusion: SIR-Spheres is a feasible alternative to systemic therapy for patients with liver dominant metastases from lung cancers. Although serious hepatotoxicity was noted in patients with advanced liver metastases, the treatment was tolerated with only reversible fatigue in the majority of patients. When the treatment was effective, the duration of local disease control after one treatment equaled or exceeded what would be expected with chemotherapy.
Other Abstracts in this Sub-Category 1. Low dose spiral computed tomography for early diagnosis of lung cancer. Results of baseline screening in 5,000 high-risk volunteers. Meeting: 2006 ASCO Annual Meeting Abstract No: 7029 First Author: G. Veronesi Category: Lung Cancer - Other: lung cancer 2. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 7062 First Author: L. Fehrenbacher Category: Lung Cancer - Other: lung cancer 3. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Meeting: 2006 ASCO Annual Meeting Abstract No: 7079 First Author: P. J. Loehrer Sr. Category: Lung Cancer - Other: lung cancer More... Abstracts by R. Murthy 1. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 17122 First Author: R. Murthy Category: Lung Cancer - Other: lung cancer More... PubMed Articles by Ravi Murthy
1. Resin (90)Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys, United States Vol 65, No 2 (5/13/2006): pp. 412-25 PMID: 16690429 [PubMed - in process] 2. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer, Vol , No (9/1/2005): pp. PMID: 16134179 [PubMed - in process] 3. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics, United States Vol 25 Suppl 1, No (10/18/2005): pp. S41-55 PMID: 16227496 [PubMed - in process] More...
This online resource is supported by:
Terms & Conditions | Privacy Policy | Sponsor | Contact Us | Conflict of Interest
Home > Abstracts & Research > Abstracts > 2006 ASCO Annual Meeting
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Sub-category: Other: lung cancer Category: Lung Cancer Meeting: 2006 ASCO Annual Meeting Printer Friendly E-Mail Article
Abstract No: 17122 Citation: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17122 Author(s): R. Murthy, Y. Oh, A. Tam, S. Gupta, D. C. Madoff, B. Glisson Abstract: Background: Hepatic metastases are a common manifestation of primary lung malignancies; the primary and other extrahepatic sites are often less responsive to systemic therapy. A new method of regional therapy for hepatic metastases, called SIR-Spheres, a 32µ resin sphere incorporating a pure Beta emitter, Yttrium - 90, has advantages to older forms of regional hepatic therapy, used to treat colorectal liver metastases. The effectiveness and relatively response durability suggests a favorable alternative to chemotherapy for patients with liver-dominant metastatic lung cancers. We report our experience using SIR-Spheres in this setting. Materials and Methods: 6 patients (2 well differentiated carcinoid, 2 well & 1 poorly differentiated adenocarcinoma, 1 poorly differentiated small cell carcinoma) with unresectable hepatic metastases were treated with 8 infusions of SIR-Spheres after failing systemic chemotherapy, radiofrequency ablation or arterial embolization were included in the study. SIR-Spheres were administered as 2nd-6th line therapy. Median interval from diagnosis to SIR-Spheres treatment was 20.5 months (6-51 m). Results: Abdominal visceral arteriography demonstrated vasculature conducive for SIR-Spheres delivery in all patients. The median dose of 36.1 mCi (12.9-54 mCi) was delivered. SPECT - CT fusion Bremsstrahlung scans post therapy confirmed preferential deposition of SIR-Spheres within metastases. Responses to therapy included a decrease in the size of the hepatic metastases in one patient and stable disease in two patients. One patient had a mixed response and two patients had progression of disease. One Gr. III and one Gr. IV hepatic toxicity occurred. All patients experienced transient Gr. 1 or 2 fatigue. Time to progression of liver disease ranged from 3 to 9 months. Conclusion: SIR-Spheres is a feasible alternative to systemic therapy for patients with liver dominant metastases from lung cancers. Although serious hepatotoxicity was noted in patients with advanced liver metastases, the treatment was tolerated with only reversible fatigue in the majority of patients. When the treatment was effective, the duration of local disease control after one treatment equaled or exceeded what would be expected with chemotherapy.
Other Abstracts in this Sub-Category 1. Low dose spiral computed tomography for early diagnosis of lung cancer. Results of baseline screening in 5,000 high-risk volunteers. Meeting: 2006 ASCO Annual Meeting Abstract No: 7029 First Author: G. Veronesi Category: Lung Cancer - Other: lung cancer 2. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 7062 First Author: L. Fehrenbacher Category: Lung Cancer - Other: lung cancer 3. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Meeting: 2006 ASCO Annual Meeting Abstract No: 7079 First Author: P. J. Loehrer Sr. Category: Lung Cancer - Other: lung cancer More... Abstracts by R. Murthy 1. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 17122 First Author: R. Murthy Category: Lung Cancer - Other: lung cancer More... PubMed Articles by Ravi Murthy
1. Resin (90)Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys, United States Vol 65, No 2 (5/13/2006): pp. 412-25 PMID: 16690429 [PubMed - in process] 2. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer, Vol , No (9/1/2005): pp. PMID: 16134179 [PubMed - in process] 3. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics, United States Vol 25 Suppl 1, No (10/18/2005): pp. S41-55 PMID: 16227496 [PubMed - in process] More...
This online resource is supported by:
Terms & Conditions | Privacy Policy | Sponsor | Contact Us | Conflict of Interest
Our Patients Say... Dr. Kennedy and staff were wonderful to me. Professional, caring, helpful, and understanding.
Sirtex Presents SIR-Spheres® Microspheres Data at the American Brachytherapy Society 2006 Meeting
Meeting marks debut of microspheres therapy for liver cancer at annual event
Philadelphia, PA. (May 10, 2006) – New research on Sirtex’s SIR-Spheres® microspheres will be presented at the 2006 American Brachytherapy Society’s annual meeting held May 10-12 in Philadelphia. Dr. Andrew Kennedy, co-medical director of Wake Radiology Oncology Services in Cary, N.C., will discuss findings of two studies involving SIR-Spheres microspheres for treatment of advanced liver cancer. Dr. Kennedy’s presentation marks the first time microspheres therapy has been featured at the ABS meeting. Sirtex’s SIR-Spheres microspheres are the only FDA-approved microspheres therapy for metastatic liver cancer.
Dr. Kennedy’s first poster presentation is a retrospective review of 18 patients who received SIR-Spheres microspheres for carcinoid tumors. Standard use of microspheres therapy for carcinoid tumors is to apply once, typically to a single lobe, followed with treatment to the second lobe one month later. Dr. Kennedy evaluated the outcome of treating all tumors during each treatment, a process known as whole liver therapy. A second and third treatment was given to control of large lesions.
Following brachytherapy, participants were monitored with regular laboratory and imaging studies. Eighty-nine percent of patients responded to the treatment, with a median follow-up period of 27 months. Researchers concluded that whole liver and multiple treatments with microspheres brachytherapy are safe and produce a high response rate, even with large tumors.
"We are grateful to Dr. Kennedy for his ongoing microspheres research," says Dr. David Cade, medical director for Sirtex. "Carcinoid tumors are historically difficult to treat. By offering a whole liver approach, this data suggests we are able to treat patients more effectively and increase response rates."
Dr. Kennedy also will present a poster analyzing the current dosing guidelines for SIR-Spheres microspheres. His team compared the current dose planning recommendations with his own dosing formula based on tumor volume and prescribed amount of radioactivity. Though Dr. Kennedy’s formula resulted in 20-30 percent less radioactivity, it enabled a more consistent delivery of microspheres. The reduced activity lowered the risk of radiation-induced liver damage, but did not decrease tumor response.
"Choosing the appropriate microspheres dose is critical," Dr. Kennedy says. "We use this formula in our practice and have had no severe complications or reactions from dosing. The goal is to deliver the most effective dose to the tumor site, but not prescribe too much activity, which can result in liver toxicity or additional disposal concerns for the treating team."
Abstracts on both research papers will be available in the May issue of the journal Brachytherapy. The publication is the official journal of the American Brachytherapy Society.
About SIR-Spheres® Microspheres SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of microspheres directly to the tumor site. The SIR-Spheres microspheres target the liver tumors sparing healthy liver tissue. Approximately 100 physicians in the United States use Sirtex’s SIR-Spheres microspheres in more than 75 medical centers.
About Sirtex SIR-Spheres microspheres were developed in the 1980s in Australia and gained FDA approval in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, please visit www.sirtex.com.
Home | Forums | Site News | NEW ALERTS Logout | My : Favourites : Account
Lookup
Search
Public Forums Latest posts ASX - by stock ASX - General AIM - London US Stocks General Humour Feedback
Users Online 213 Logins Today
Member Forums List Forums Create Member Forum
Post Msg.
Subject: Message text: Here they are; SEARCH
SIGN IN | REGISTER | ADVANCED SEARCH
1900 Duke Street, Suite 200 | Alexandria, VA 22314
Meetings Abstracts & Research Abstracts Virtual Meeting Annual Meeting Summaries NICCQ Central Review of Clinical Trials Grants Clinical Trials Awards Practice Resources Education & Training News Legislative & Regulatory
About ASCO ASCO Bookstore Careers in Oncology Downloads & Technology Grants Membership State Affiliates
Home > Abstracts & Research > Abstracts > 2006 ASCO Annual Meeting
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Sub-category: Other: lung cancer Category: Lung Cancer Meeting: 2006 ASCO Annual Meeting Printer Friendly E-Mail Article
Abstract No: 17122 Citation: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17122 Author(s): R. Murthy, Y. Oh, A. Tam, S. Gupta, D. C. Madoff, B. Glisson Abstract: Background: Hepatic metastases are a common manifestation of primary lung malignancies; the primary and other extrahepatic sites are often less responsive to systemic therapy. A new method of regional therapy for hepatic metastases, called SIR-Spheres, a 32µ resin sphere incorporating a pure Beta emitter, Yttrium - 90, has advantages to older forms of regional hepatic therapy, used to treat colorectal liver metastases. The effectiveness and relatively response durability suggests a favorable alternative to chemotherapy for patients with liver-dominant metastatic lung cancers. We report our experience using SIR-Spheres in this setting. Materials and Methods: 6 patients (2 well differentiated carcinoid, 2 well & 1 poorly differentiated adenocarcinoma, 1 poorly differentiated small cell carcinoma) with unresectable hepatic metastases were treated with 8 infusions of SIR-Spheres after failing systemic chemotherapy, radiofrequency ablation or arterial embolization were included in the study. SIR-Spheres were administered as 2nd-6th line therapy. Median interval from diagnosis to SIR-Spheres treatment was 20.5 months (6-51 m). Results: Abdominal visceral arteriography demonstrated vasculature conducive for SIR-Spheres delivery in all patients. The median dose of 36.1 mCi (12.9-54 mCi) was delivered. SPECT - CT fusion Bremsstrahlung scans post therapy confirmed preferential deposition of SIR-Spheres within metastases. Responses to therapy included a decrease in the size of the hepatic metastases in one patient and stable disease in two patients. One patient had a mixed response and two patients had progression of disease. One Gr. III and one Gr. IV hepatic toxicity occurred. All patients experienced transient Gr. 1 or 2 fatigue. Time to progression of liver disease ranged from 3 to 9 months. Conclusion: SIR-Spheres is a feasible alternative to systemic therapy for patients with liver dominant metastases from lung cancers. Although serious hepatotoxicity was noted in patients with advanced liver metastases, the treatment was tolerated with only reversible fatigue in the majority of patients. When the treatment was effective, the duration of local disease control after one treatment equaled or exceeded what would be expected with chemotherapy.
Other Abstracts in this Sub-Category 1. Low dose spiral computed tomography for early diagnosis of lung cancer. Results of baseline screening in 5,000 high-risk volunteers. Meeting: 2006 ASCO Annual Meeting Abstract No: 7029 First Author: G. Veronesi Category: Lung Cancer - Other: lung cancer 2. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 7062 First Author: L. Fehrenbacher Category: Lung Cancer - Other: lung cancer 3. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Meeting: 2006 ASCO Annual Meeting Abstract No: 7079 First Author: P. J. Loehrer Sr. Category: Lung Cancer - Other: lung cancer More... Abstracts by R. Murthy 1. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 17122 First Author: R. Murthy Category: Lung Cancer - Other: lung cancer More... PubMed Articles by Ravi Murthy
1. Resin (90)Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys, United States Vol 65, No 2 (5/13/2006): pp. 412-25 PMID: 16690429 [PubMed - in process] 2. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer, Vol , No (9/1/2005): pp. PMID: 16134179 [PubMed - in process] 3. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics, United States Vol 25 Suppl 1, No (10/18/2005): pp. S41-55 PMID: 16227496 [PubMed - in process] More...
This online resource is supported by:
Terms & Conditio SEARCH
SIGN IN | REGISTER | ADVANCED SEARCH
1900 Duke Street, Suite 200 | Alexandria, VA 22314
Meetings Abstracts & Research Abstracts Virtual Meeting Annual Meeting Summaries NICCQ Central Review of Clinical Trials Grants Clinical Trials Awards Practice Resources Education & Training News Legislative & Regulatory
About ASCO ASCO Bookstore Careers in Oncology Downloads & Technology Grants Membership State Affiliates
Home > Abstracts & Research > Abstracts > 2006 ASCO Annual Meeting
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Sub-category: Other: lung cancer Category: Lung Cancer Meeting: 2006 ASCO Annual Meeting Printer Friendly E-Mail Article
Abstract No: 17122 Citation: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17122 Author(s): R. Murthy, Y. Oh, A. Tam, S. Gupta, D. C. Madoff, B. Glisson Abstract: Background: Hepatic metastases are a common manifestation of primary lung malignancies; the primary and other extrahepatic sites are often less responsive to systemic therapy. A new method of regional therapy for hepatic metastases, called SIR-Spheres, a 32µ resin sphere incorporating a pure Beta emitter, Yttrium - 90, has advantages to older forms of regional hepatic therapy, used to treat colorectal liver metastases. The effectiveness and relatively response durability suggests a favorable alternative to chemotherapy for patients with liver-dominant metastatic lung cancers. We report our experience using SIR-Spheres in this setting. Materials and Methods: 6 patients (2 well differentiated carcinoid, 2 well & 1 poorly differentiated adenocarcinoma, 1 poorly differentiated small cell carcinoma) with unresectable hepatic metastases were treated with 8 infusions of SIR-Spheres after failing systemic chemotherapy, radiofrequency ablation or arterial embolization were included in the study. SIR-Spheres were administered as 2nd-6th line therapy. Median interval from diagnosis to SIR-Spheres treatment was 20.5 months (6-51 m). Results: Abdominal visceral arteriography demonstrated vasculature conducive for SIR-Spheres delivery in all patients. The median dose of 36.1 mCi (12.9-54 mCi) was delivered. SPECT - CT fusion Bremsstrahlung scans post therapy confirmed preferential deposition of SIR-Spheres within metastases. Responses to therapy included a decrease in the size of the hepatic metastases in one patient and stable disease in two patients. One patient had a mixed response and two patients had progression of disease. One Gr. III and one Gr. IV hepatic toxicity occurred. All patients experienced transient Gr. 1 or 2 fatigue. Time to progression of liver disease ranged from 3 to 9 months. Conclusion: SIR-Spheres is a feasible alternative to systemic therapy for patients with liver dominant metastases from lung cancers. Although serious hepatotoxicity was noted in patients with advanced liver metastases, the treatment was tolerated with only reversible fatigue in the majority of patients. When the treatment was effective, the duration of local disease control after one treatment equaled or exceeded what would be expected with chemotherapy.
Other Abstracts in this Sub-Category 1. Low dose spiral computed tomography for early diagnosis of lung cancer. Results of baseline screening in 5,000 high-risk volunteers. Meeting: 2006 ASCO Annual Meeting Abstract No: 7029 First Author: G. Veronesi Category: Lung Cancer - Other: lung cancer 2. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 7062 First Author: L. Fehrenbacher Category: Lung Cancer - Other: lung cancer 3. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Meeting: 2006 ASCO Annual Meeting Abstract No: 7079 First Author: P. J. Loehrer Sr. Category: Lung Cancer - Other: lung cancer More... Abstracts by R. Murthy 1. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Meeting: 2006 ASCO Annual Meeting Abstract No: 17122 First Author: R. Murthy Category: Lung Cancer - Other: lung cancer More... PubMed Articles by Ravi Murthy
1. Resin (90)Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys, United States Vol 65, No 2 (5/13/2006): pp. 412-25 PMID: 16690429 [PubMed - in process] 2. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer, Vol , No (9/1/2005): pp. PMID: 16134179 [PubMed - in process] 3. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics, United States Vol 25 Suppl 1, No (10/18/2005): pp. S41-55 PMID: 16227496 [PubMed - in process] More...
This online resource is supported by:
Terms & Conditions | Privacy Policy | Sponsor | Contact Us | Conflict of Interest
ns | Privacy Policy | Sponsor | Contact Us | Conflict of Interest
Our Patients Say... Dr. Kennedy and staff were wonderful to me. Professional, caring, helpful, and understanding.
Sirtex Presents SIR-Spheres® Microspheres Data at the American Brachytherapy Society 2006 Meeting
Meeting marks debut of microspheres therapy for liver cancer at annual event
Philadelphia, PA. (May 10, 2006) – New research on Sirtex’s SIR-Spheres® microspheres will be presented at the 2006 American Brachytherapy Society’s annual meeting held May 10-12 in Philadelphia. Dr. Andrew Kennedy, co-medical director of Wake Radiology Oncology Services in Cary, N.C., will discuss findings of two studies involving SIR-Spheres microspheres for treatment of advanced liver cancer. Dr. Kennedy’s presentation marks the first time microspheres therapy has been featured at the ABS meeting. Sirtex’s SIR-Spheres microspheres are the only FDA-approved microspheres therapy for metastatic liver cancer.
Dr. Kennedy’s first poster presentation is a retrospective review of 18 patients who received SIR-Spheres microspheres for carcinoid tumors. Standard use of microspheres therapy for carcinoid tumors is to apply once, typically to a single lobe, followed with treatment to the second lobe one month later. Dr. Kennedy evaluated the outcome of treating all tumors during each treatment, a process known as whole liver therapy. A second and third treatment was given to control of large lesions.
Following brachytherapy, participants were monitored with regular laboratory and imaging studies. Eighty-nine percent of patients responded to the treatment, with a median follow-up period of 27 months. Researchers concluded that whole liver and multiple treatments with microspheres brachytherapy are safe and produce a high response rate, even with large tumors.
"We are grateful to Dr. Kennedy for his ongoing microspheres research," says Dr. David Cade, medical director for Sirtex. "Carcinoid tumors are historically difficult to treat. By offering a whole liver approach, this data suggests we are able to treat patients more effectively and increase response rates."
Dr. Kennedy also will present a poster analyzing the current dosing guidelines for SIR-Spheres microspheres. His team compared the current dose planning recommendations with his own dosing formula based on tumor volume and prescribed amount of radioactivity. Though Dr. Kennedy’s formula resulted in 20-30 percent less radioactivity, it enabled a more consistent delivery of microspheres. The reduced activity lowered the risk of radiation-induced liver damage, but did not decrease tumor response.
"Choosing the appropriate microspheres dose is critical," Dr. Kennedy says. "We use this formula in our practice and have had no severe complications or reactions from dosing. The goal is to deliver the most effective dose to the tumor site, but not prescribe too much activity, which can result in liver toxicity or additional disposal concerns for the treating team."
Abstracts on both research papers will be available in the May issue of the journal Brachytherapy. The publication is the official journal of the American Brachytherapy Society.
About SIR-Spheres® Microspheres SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of microspheres directly to the tumor site. The SIR-Spheres microspheres target the liver tumors sparing healthy liver tissue. Approximately 100 physicians in the United States use Sirtex’s SIR-Spheres microspheres in more than 75 medical centers.
About Sirtex SIR-Spheres microspheres were developed in the 1980s in Australia and gained FDA approval in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, please visit www.sirtex.com.
Sirtex Presents SIR-Spheres(R) Microspheres Data at the American Brachytherapy Society 2006 Meeting Tuesday May 9, 10:42 am ET Meeting marks debut of microspheres therapy for liver cancer at annual event
PHILADELPHIA--(BUSINESS WIRE)--May 9, 2006--New research on Sirtex's SIR-Spheres® microspheres will be presented at the 2006 American Brachytherapy Society's annual meeting held May 10-12 in Philadelphia. Dr. Andrew Kennedy, co-medical director of Wake Radiology Oncology Services in Cary, N.C., will discuss findings of two studies involving SIR-Spheres microspheres for treatment of advanced liver cancer. Dr. Kennedy's presentation marks the first time microspheres therapy has been featured at the ABS meeting. Sirtex's SIR-Spheres microspheres are the only FDA-approved microspheres therapy for metastatic liver cancer. ADVERTISEMENT
Dr. Kennedy's first poster presentation is a retrospective review of 18 patients who received SIR-Spheres microspheres for carcinoid tumors. Standard use of microspheres therapy for carcinoid tumors is to apply once, typically to a single lobe, followed with treatment to the second lobe one month later. Dr. Kennedy evaluated the outcome of treating all tumors during each treatment, a process known as whole liver therapy. A second and third treatment was given to control large lesions.
Following brachytherapy, participants were monitored with regular laboratory and imaging studies. Eighty-nine percent of patients responded to the treatment, with a median follow-up period of 27 months. Researchers concluded that whole liver and multiple treatments with microspheres brachytherapy are safe and produce a high response rate, even with large tumors.
"We are grateful to Dr. Kennedy for his ongoing microspheres research," says Dr. David Cade, medical director for Sirtex. "Carcinoid tumors are historically difficult to treat. By offering a whole liver approach, this data suggests we are able to treat patients more effectively and increase response rates."
Dr. Kennedy also will present a poster analyzing the current dosing guidelines for SIR-Spheres microspheres. His team compared the current dose planning recommendations with his own dosing formula based on tumor volume and prescribed amount of radioactivity. Though Dr. Kennedy's formula resulted in 20-30 percent less radioactivity, it enabled a more consistent delivery of microspheres. The reduced activity lowered the risk of radiation-induced liver damage, but did not decrease tumor response.
"Choosing the appropriate microspheres dose is critical," Dr. Kennedy says. "We use this formula in our practice and have had no severe complications or reactions from dosing. The goal is to deliver the most effective dose to the tumor site, but not prescribe too much activity, which can result in liver toxicity or additional disposal concerns for the treating team."
Abstracts on both research papers will be available in the May issue of the journal Brachytherapy. The publication is the official journal of the American Brachytherapy Society.
About SIR-Spheres Microspheres
SIR-Spheres® microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of microspheres directly to the tumor site. The SIR-Spheres microspheres target the liver tumors sparing healthy liver tissue. Approximately 100 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 75 medical centers.
About Sirtex
SIR-Spheres microspheres were developed in the 1980s in Australia and gained FDA approval in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, visit www.sirtex.com.
Sponsor Results Financial Advisor Courses Earn your financial planning certificate 100% online. Free info here. www.kaplan-degrees.com Find a Financial Advisor Use our free matching service to find a local financial advisor. www.wiseradvisor.com A Financial Advisor Search Find top-rated financial advisors in your area from Advisor Now, a free matching service. www.advisornow.com
(What's This?)
Top Stories · Oil Company Execs Defend High Pump Prices - AP (12:12 pm) · Bernanke's Dilemma: Avoiding a Recession - AP (12:34 pm) · Wall Street's Focus to Shift to Earnings - AP (2:00 pm) · Skilling Tells Paper He Considered Suicide - AP (12:57 am) More...
Our Patients Say... Dr. Kennedy and staff were wonderful to me. Professional, caring, helpful, and understanding.
In The News » Sirtex Presents SIR-Spheres Microspheres Data
BREAKING CLINICAL NEWS
Sirtex Presents SIR-Spheres® Microspheres Data at the American Brachytherapy Society 2006 Meeting
Meeting marks debut of microspheres therapy for liver cancer at annual event
Philadelphia, PA. (May 10, 2006) – New research on Sirtex’s SIR-Spheres® microspheres will be presented at the 2006 American Brachytherapy Society’s annual meeting held May 10-12 in Philadelphia. Dr. Andrew Kennedy, co-medical director of Wake Radiology Oncology Services in Cary, N.C., will discuss findings of two studies involving SIR-Spheres microspheres for treatment of advanced liver cancer. Dr. Kennedy’s presentation marks the first time microspheres therapy has been featured at the ABS meeting. Sirtex’s SIR-Spheres microspheres are the only FDA-approved microspheres therapy for metastatic liver cancer.
Dr. Kennedy’s first poster presentation is a retrospective review of 18 patients who received SIR-Spheres microspheres for carcinoid tumors. Standard use of microspheres therapy for carcinoid tumors is to apply once, typically to a single lobe, followed with treatment to the second lobe one month later. Dr. Kennedy evaluated the outcome of treating all tumors during each treatment, a process known as whole liver therapy. A second and third treatment was given to control of large lesions.
Following brachytherapy, participants were monitored with regular laboratory and imaging studies. Eighty-nine percent of patients responded to the treatment, with a median follow-up period of 27 months. Researchers concluded that whole liver and multiple treatments with microspheres brachytherapy are safe and produce a high response rate, even with large tumors.
"We are grateful to Dr. Kennedy for his ongoing microspheres research," says Dr. David Cade, medical director for Sirtex. "Carcinoid tumors are historically difficult to treat. By offering a whole liver approach, this data suggests we are able to treat patients more effectively and increase response rates."
Dr. Kennedy also will present a poster analyzing the current dosing guidelines for SIR-Spheres microspheres. His team compared the current dose planning recommendations with his own dosing formula based on tumor volume and prescribed amount of radioactivity. Though Dr. Kennedy’s formula resulted in 20-30 percent less radioactivity, it enabled a more consistent delivery of microspheres. The reduced activity lowered the risk of radiation-induced liver damage, but did not decrease tumor response.
"Choosing the appropriate microspheres dose is critical," Dr. Kennedy says. "We use this formula in our practice and have had no severe complications or reactions from dosing. The goal is to deliver the most effective dose to the tumor site, but not prescribe too much activity, which can result in liver toxicity or additional disposal concerns for the treating team."
Abstracts on both research papers will be available in the May issue of the journal Brachytherapy. The publication is the official journal of the American Brachytherapy Society.
About SIR-Spheres® Microspheres SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of microspheres directly to the tumor site. The SIR-Spheres microspheres target the liver tumors sparing healthy liver tissue. Approximately 100 physicians in the United States use Sirtex’s SIR-Spheres microspheres in more than 75 medical centers.
About Sirtex SIR-Spheres microspheres were developed in the 1980s in Australia and gained FDA approval in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, please visit www.sirtex.com.
(20min delay)